XML 15 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Compensation (Narrative) (Detail) (USD $)
In Millions, except Share data, unless otherwise specified
6 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Stock Option
Jun. 30, 2012
Restricted Stock Units
Apr. 19, 2012
Amendment 1993 Plan
Jun. 30, 2012
1993 Plan
Dec. 31, 2011
1993 Plan
Jun. 30, 2012
Stock Options And Stock-Settled SARS
Jun. 30, 2011
Stock Options And Stock-Settled SARS
Jun. 30, 2012
Stock Options And Stock-Settled SARS
Jun. 30, 2011
Stock Options And Stock-Settled SARS
Jun. 30, 2012
Cash-Settled SARS
Jun. 30, 2011
Cash-Settled SARS
Jun. 30, 2012
Cash-Settled SARS
Jun. 30, 2011
Cash-Settled SARS
Dec. 31, 2011
Cash-Settled SARS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                
Increase in number of shares issuable under the plan         2,000,000                      
Shares reserved for issuance           6,400,000                    
Shares reserved for issuance for all outstanding share-based compensation grants           3,600,000                    
Stock option grant component, percentage of market price                   100.00%            
Contractual life (years)                   10 years            
Stock awards granted 470,809                 470,809            
Weighted-average grant-date fair value $ 19.91 $ 20.83               $ 19.91 $ 20.83          
Total intrinsic value of stock options and stock-settled SARS exercised                   $ 14.9 $ 5.7          
Total fair value of stock options and stock-settled SARS vested                   6.5 6.8          
Pre-tax compensation cost related to stock option and stock-settled SARS               2.5 1.8 4.6 3.7          
Liability for awards 2.9             11.1   11.1            
Weighted-average period to recognize total unrecognized compensation cost (years)                   1 year 3 months            
Vesting period for majority of awards (years)                   3 years            
Tax benefits realized                   5.0 2.1          
Cash received from stock options exercised 16.3 5.6               16.3 5.6          
Intrinsic value and cash used to settle exercises of cash-settled SARS                       0.1 0.1      
Pre-tax expense (income) recognized for cash-settled SARS                           0.6 (2.2)  
Liability related to cash-settled SARS                       1.6   1.6   1.3
Compensation cost recognized           0.6 0.3                  
Additional paid-in capital representing excess tax benefits available to absorb potential future tax deficiencies           75.3 71.7                  
Reclassified shares of options     184,823 38,401                        
Previously recognized expense out of additional paid in capital 1.7                              
Recognized additional expense $ 1.2